Animation prostate – Medical Animation Prostate Cancer

Family History Of Prostate Cancer Does Not Affect Some Treatment Outcomes
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics sim

Why Prostate Cancer Patients Fail Hormone Deprivation
The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings, reported in the Jan.

Why Prostate Cancer Patients Fail Hormone Deprivation Therapy
The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings, reported in the Jan.

Two Compounds In The Trofexâ„¢ Prostate Cancer Molecular Imaging Program Specifically Target Prostate Cancer Cells
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today the publication of a preclinical study describing the synthesis and initial evaluation of two series of radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer.

GTx Submits New Drug Application For Toremifene 80 Mg For Prevention Of Bone Fractures In Men With Prostate Cancer On Androgen Deprivation Therapy
GTx, Inc. (Nasdaq: GTXI) today announced the submission of a New Drug Application with the U.S. Food and Drug Administration (FDA) for toremifene 80 mg, an oral selective estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT). "ADT has helped improve survival for men with advanced prostate cancer.

FDA Approves Drug For Patients With Advanced Prostate Cancer
The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.

Gay And Bisexual African-American Men Have The Lowest Use Of Prostate Testing
Gay and bisexual black men are less likely to be tested for prostate cancer than men of any other racial and ethnic backgrounds regardless of their sexual orientation, according to a recent study by a researcher at Charles Drew University of Medicine and Science. In his study, published in the December issue of Medical Care, Kevin C.

FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) For Treatment Of Advanced Prostate Cancer
Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA. Following issuance of a trade name, Ferring Pharmaceuticals, USA will immediately begin commercialization in the U.S.

Ingredient In Cough Medicine Could Effectively Treat Prostate Cancer
A study published in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Researchers found that noscapine, which has been used in cough medication for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.

Change Determinants In PSA Over Time - Its Association With Recurrence After External Beam Radiation Therapy For Prostate Cancer In 5 Large Cohorts
UroToday.com - In the November 1, 2008 issue of International Journal of Radiation Oncology, Biology, Physics, Dr. Cécile Proust-Lima and colleagues presented a linear mixed model to construct patient PSA profiles after radiotherapy (XRT) for prostate cancer (CaP). The included XRT data from 5 patient cohorts where men with CaP were treated for clinically localized disease.

Oncologic Outcome After Laparoscopic Radical Prostatectomy: 10 Years Of Experience
UroToday.com - Long-term oncologic outcomes for laparoscopic radical prostatectomy (LRP) are lacking. In the online edition of European Urology, Dr. Karim Touijer and associates from Dr. Bertrand Guillonneau's group published their 10-year oncologic results following LRP. Between 1998 and 2007, 1,564 consecutive patients underwent LRP; first at Montsouris Institute in Paris, then subsequently at Memorial Sloan-Kettering Cancer Center in New York.

Common Treatment For Men's Pelvic Pain Proves Ineffective, Queen's-led Study Shows
A commonly-prescribed drug for men suffering from a painful pelvic condition failed to significantly reduce patients' symptoms in an international study led by Queen's University professor and urologist at Kingston General Hospital, Curtis Nickel. The drug, called Alfuzosin, is regularly prescribed by more than half of family doctors to treat chronic prostititis/chronic pelvic pain syndrome. This affliction is estimated to affect from six to 12 per cent of the population.

Relief By Botulinum Toxin Of Lower Urinary Tract Symptoms Owing To Benign Prostatic Hyperplasia: Early And Long-Term Results
UroToday.com - Botulinum toxin (BTX) is used therapeutically for several disorders associated with excessive muscular contractions including focal dystonias. Recently BTX has been successfully used for the treatment of disorders of the gastrointestinal and urinary tracts. Nevertheless, controversy exists regarding safety of this treatment.

Seed Displacements After Permanent Brachytherapy For Prostate Cancer In Dependence On The Prostate Level
UroToday.com - Interstitial brachytherapy became an established treatment for localized prostate cancer in the last decade with excellent long-term results. CT-based dosimetry is currently recommended as the standard for postimplant dosimetry, with a suggested interval of four weeks after I-125 brachytherapy. For practical and logistic reasons many brachytherapists prefer to rely on early scanning.

CHMP Recommends Granting Marketing Authorisation For FIRMAGON(R) (degarelix) For Treatment Of Prostate Cancer
Ferring Pharmaceuticals received notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer.